Nextech Invest — Full Portfolio

Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors.

BiotechBoston, US

AHAlan Huang(Executive Officer)inACAdam Crystal(Executive Officer)inDBDaniella Beckman(Executive Officer)inDouglas Barry(Executive Officer)Aaron Davis(Director)

BoardBWBarbara Weber(Executive Officer, Director)in

Board seatKPKanishka Pothula· per SEC Form D

Co-investorsFOForesite CapitalNSNSG VenturesRORoche Venture FundTHThird Rock Ventures

Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.

AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US

MBMartin Babler(President, Chief Executive Officer and Chairman of the Board)inMBMark Bradley(Chief Development Officer)inKBKolbot By(SVP, Head of Technical Operations)inJDJack Danilkowicz(Chief Commercial Officer)inJDJörn Drappa(Chief Medical Officer)inDMDavid M Goldstein(Chief Scientific Officer)in

Co-investorsFOForesite CapitalGEGeneral AtlanticHBHBM Healthcare InvestmentsHBHBM PartnersOROrbiMedSASamsara BioCapital+4 more

Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.

BiotechHealthtechNew Haven, US

SCSean Cassidy(Executive Officer)inMLManuel Litchman(Executive Officer, Director)inRTRandy Teel(President and Chief Executive Officer; Director)inCraig Crews(Founder)

BoardSSStephen Squinto(Director)inLRLiam Ratcliffe(Director)in

Co-investors5A5AM VenturesACAccess BiotechnologyCACanaan PartnersCOConnecticut InnovationsELElm Street VenturesRARA Capital+3 more

Autolus Therapeutics develops engineered T cell therapies targeting cancer and autoimmune diseases using proprietary cell programming technology; the company commercializes AUCATZYL, an FDA-approved CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia in adults, and maintains a clinical pipeline evaluating additional indications including pediatric leukemia, lupus nephritis, and multiple sclerosis.

London

Martin Pulé(Senior Vice President, Founder, Chief Scientific Officer)Christopher Williams(Senior Vice President, Chief Business Development Officer)Edgar Braendle(Executive Officer)inCVChristopher Vann(Executive Officer)inDavid Brochu(Executive Officer)inChristian Itin(Chief Executive Officer and Director)in

Black Diamond Therapeutics develops small-molecule kinase inhibitors targeting families of oncogenic mutations across cancer types, including its lead candidate silevertinib for EGFR-mutant lung cancer and glioblastoma.

EBElizabeth Buck(Chief Scientific Officer)inBrent Hatzis-Schoch(Chief Operating Officer and General Counsel)inSYSergey Yurasov(Chief Medical Officer)inMelanie Morrison(Chief Development Officer)

Co-investorsLALAVLILilly Asia VenturesNENew Enterprise Associates (NEA)NSNSG VenturesRARA CapitalVEVersant Ventures+4 more

Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.

BiotechMedical DevicesLa Jolla, US

ZDZachary D. Hornby(Executive Officer, Director)inRDRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)JOJessica Oien(Chief Legal Officer and Corporate Secretary)in

BoardBenjamin Cravatt, Ph.D.(Director)KBKristina Burow(Director)in

Co-investorsARARCH Venture PartnersRARA CapitalVEVertex Ventures HCWEWellington ManagementALAlexandriaCICity Hill Ventures+3 more

C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease.

BiotechCambridge, US

KCKenneth C. Anderson(Director)Andrew J. Hirsch(President and Chief Executive Officer)in

BoardMarc Cohen(Executive Officer, Director)inJason Fisherman(Executive Officer, Director)Miles Stuchin(Director)Bruce Downey(Director)

Co-investors3E3E Bioventures CapitalBABain Capital Life SciencesRARA CapitalRORoche Venture FundCOCobro Ventures

Context Therapeutics develops clinical-stage T cell engaging bispecific antibody therapies for the treatment of solid tumors.

BiotechHealthtechPhiladelphia, US

MLMartin Lehr(Founder)inJMJennifer Minai-Azary(Executive Officer)inALAlex Levit(Executive Officer)Linda Beth West(Director)Richard Jay Berman(Director)PKPhilip Kantoff(Director)in

Co-investorsOUOUP (Osage University Partners)TOTorrey Pines Investment

Cullinan Therapeutics is a clinical-stage biotech company developing therapeutic molecules for autoimmune diseases and cancer, with expertise in immune modulation.

BiotechHealthtechMedical Devices

MKMary Kay Fenton(Chief Financial Officer)inJeffrey Jones(Chief Medical Officer)JMJennifer Michaelson(Chief Scientific Officer)inCorinne Savill(Chief Business Officer)inJacquelyn Sumer(Chief Legal and Compliance Officer and Secretary)inNANadim Ahmed(President and Chief Executive Officer)in

Co-investorsFOForesite CapitalBIBiotechnology Value FundOROrbiMed

IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers.

BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US

PSPaul Stone(Executive Officer)inYujiro S. Hata(President, Chief Executive Officer and Director)

BoardTSTimothy Shannon(Director)inJDJohn Diekman(Director)inTRTerry Rosen(Director)JSJeffrey Stein(Director)

Co-investors5A5AM VenturesCACanaan PartnersGVGV (Google Ventures)RORoche Venture FundBIBiotechnology Value FundWUWuXi Healthcare Ventures

Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.

BiotechDigital HealthMedical DevicesLa Jolla, US

PINGDA REN(Executive Officer)inYLYI LIU(Executive Officer)inTWTroy Wilson(Founder)inTWTroy Wilson, Ph.D., J.D.(Co-founder; President, Chief Executive Officer and Chairman of the Board)Kevan M. Shokat, Ph.D.(Founding team member)HEIDI HENSON(Executive Officer)in

Co-investorsARARCH Venture PartnersAVAvoro Capital AdvisorsECEcoR1 CapitalFOForesite CapitalOUOUP (Osage University Partners)

Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.

BiotechDeep TechHealthtech

NMNello Mainolfi(Founder)inBBBruce Booth(Chair)in

Co-investorsATAtlas VentureAVAvoro Capital AdvisorsBABain Capital Life SciencesBEBessemer Venture PartnersHAHatteras Venture PartnersMRMRL Ventures Fund+7 more

ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance.

BiotechHealthtechSouth San Francisco, US

RHRichard Heyman(Chairman, Founder, Scientific Advisory Board)inCSCharles Sawyers(Founder, Scientific Advisory Board)Scott Lowe(Founder, Scientific Advisory Board)DPDominic Piscitelli(Chief Financial Officer)inPMPratik Multani(Chief Medical Officer)inJCJacob Chacko(President, Chief Executive Officer and Board Member)in

Co-investorsECEcoR1 CapitalNENew Enterprise Associates (NEA)TATaiho Ventures, LLCTHThe Column GroupVIViking GlobalOROrbiMed

Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.

AI & Machine LearningBiotechDeep TechMedical Devices

MMMathai Mammen(CEO, President and Chairman)in

Co-investorsARARCH Venture PartnersCACatalio Capital Management, LPDEDeerfield Management CompanyFOForesite CapitalFRFrazier Life SciencesGEGeneral Catalyst+9 more

Relay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques.

AI & Machine LearningBiotechDeep TechCambridge, US

Donald A. Bergstrom(Executive Officer)inSKSanjiv K. Patel(Director, President and Chief Executive Officer)inSekar Kathiresan(Director)Douglas S. Ingram(Director)Mark Murcko(Director)Laura Shawver(Director)

Co-investorsCOCommonweal VenturesECEcoR1 CapitalFOForesite CapitalNANat TurnerSOSoftBank Vision FundCUCurie.Bio+2 more

Silence Therapeutics is a biotechnology company that discovers and develops short interfering RNA (siRNA) molecules designed to reduce the production of disease-associated proteins through the natural mechanism of RNA interference, with its proprietary mRNAi GOLD platform targeting specific genes in the liver for rare and common diseases.

BiotechLondon

Craig Tooman(Executive Officer)inGiles Campion(Executive Officer)Mark Rothera(Executive Officer, Director)inBarbara Ruskin(Executive Officer)

BoardJames Ede-Golightly(Director)Alistair Gray(Director)

Co-investorsFOForesite CapitalMCMC Healthcare VenturesVIVivo Capital

Tyra is developing oral dabogratinib, a small-molecule therapy being evaluated in clinical studies for skeletal dysplasia and urologic cancers.

BiotechHealthtechCarlsbad, US

Todd Harris, Ph.D.(Executive Officer, Director)Hiroomi Tada, M.D., Ph.D.(Executive Officer)Daniel Bensen(Executive Officer)inAlan Fuhrman(Executive Officer)inTHTodd Harris(President, Chief Executive Officer and Director)inBhavesh Ashar(Chief Operating Officer)in

Co-investorsALAlta PartnersBIBioBritCACanaan PartnersRARA Capital

Zymeworks is a biotechnology company that develops novel therapeutics for patients with difficult-to-treat diseases using its proprietary drug-development platforms and in-house R&D.

BiotechHealthtechVancouver, US

ATALI TEHRANI(Executive Officer, Director)inGORDON NG(Executive Officer)NKNEIL KLOMPAS(Executive Officer)inSDSURJIT DIXIT(Executive Officer)inDAVID TUCKER(Executive Officer)Paul Moore(Chief Scientific Officer)in

Co-investorsBRBrace PharmaCTCTI Life Sciences Fund L.P.HBHBM Healthcare InvestmentsLULumira VenturesWUWUTIF CapitalAMAmplitude Venture Capital

BiotechBurlingame, US

Mark Rolfe(Executive Officer)LSLaura Shawver(Executive Officer, Director)inTimothy Smith(Executive Officer)

BoardPTPeter Thompson(Director)inCGCarol Gallagher(Director)in

Board seatASAlfred Scheidegger· per SEC Form D

Co-investorsASAstellas Venture Management LLCNENew Enterprise Associates (NEA)OUOUP (Osage University Partners)5A5AM VenturesCLClarus VenturesOROrbiMed+1 more

Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.

AI & Machine LearningBiotechDeep TechPrinceton, US

BCBen Cravatt(Scientific Founder)PBPhil Baran(Scientific Founder)JYJin-Quan Yu(Scientific Founder)Aleksandra Rizo(President and Chief Executive Officer)in

BoardJPJohn Park(Executive Officer)JCJohn Clarke(Executive Officer, Director)in

Board seatBCBenjamin Cravatt· per SEC Form D

Co-investorsARARCH Venture PartnersAVAvoro Capital AdvisorsCACardinal PartnersSOSoftBank Vision FundALAlexandriaALALTITUDE LIFE SCIENCE VENTURES+4 more

A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications.

BiotechDeep TechDigital HealthHealthtechMedical DevicesAgoura Hills, US

CAC. Alexander Kamb(Director)inJRJim Robinson(CEO)inScott Foraker(Executive Officer, Director)Madhavan Balachandran(Director)Michael Gallo(Director)

BoardSASrini Akkaraju(Director)in

Co-investorsCACasdin CapitalMAMana VenturesTHThe Column GroupVIVida VenturesSASamsara BioCapital

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.

BiotechDigital HealthMedical DevicesVancouver, CA

FBFrançois Bénard(Founder)KLKuo-Shyan Lin(Founder)DPDavid Perrin(Founder)

Co-investorsANAndreessen HorowitzASAscenta CapitalDEDelos CapitalFRFrazier Life SciencesGEGeneral CatalystLILightspeed Venture Partners+8 more

Alpha-9 is a clinical-stage radiopharmaceutical company developing a portfolio of targeted molecules to treat cancer cells with precision.

BiotechLongevityMedical DevicesBoston, US

Co-investorsFRFrazier Life SciencesWUWUTIF CapitalASAscenta CapitalBIBiotechnology Value FundLILightspeed Venture PartnersLOLongitude Capital+1 more

Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic.

AI & Machine LearningBiotechDeep TechSan Diego, US

EAEric A. Murphy(Executive Officer, Director, Promoter)inRyan B. Corcoran(Director, Promoter)Richard Heyman(Founder)

BoardTSThilo Schroeder(Director)inCGCarl Gordon(Director)inAGArjun Goyal(Director)in

Co-investorsCACanaan PartnersOROrbiMedVIVida VenturesDIDigitalis VenturesNVNVIDIA

Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.

BiotechDeep TechMedical DevicesEindhoven, US

COChristian Ottmann(Executive Officer)inJosh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)

Co-investorsDRDroia VenturesINInkefMIMission BiocapitalMRMRL Ventures FundRARA Capital

Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.

AI & Machine LearningBiotechDeep TechHealthtechCambridge, US

MGMichael Gilman(Executive Officer, Director)inMDMark DeLong(CEO)inDNDavid Neafus(Executive Officer)inRussell C. Petter(Executive Officer)

BoardCCColleen Cuffaro(Director)inAEAlan E. Walts(Director)in

Co-investorsCACanaan PartnersPFPfizer VenturesADAdvent Life SciencesHBHBM Healthcare InvestmentsHBHBM PartnersOUOUP (Osage University Partners)+2 more

ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies.

BiotechHealthtechMedical DevicesSan Diego, US

Richard Lowenthal(Executive Officer, Director)inPratik Shah(Director)

BoardJonathan Leff(Director)

Co-investorsOROrbiMedRARA CapitalSRSR One Capital ManagementSOSofinnova Ventures

Atavistik Bio develops selective allosteric therapeutics using a proprietary discovery platform designed to identify functional pockets across multiple protein classes, with an internal focus on rare hematology.

BiotechHealthtechMedical Devices

Bryan E. Stuart(Chief Executive Officer)inMDMarion Dorsch(President and Chief Scientific Officer)inJared Rutter(Founder)John Tallarico(Founder)Ralph DeBerardinis(Founder)

Co-investorsLULux CapitalRARA CapitalTHThe Column Group

Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.

BiotechDigital Health

ZOZaneta Odrowaz(Founder)inTFTao Fu, MBA, M.S.(Founder, Chief Executive Officer, and President)ZOZaneta Odrowaz, Ph.D.(Chief Business Officer and Co-Founder)Petter Veiby(Chief Scientific Officer and Co-Founder)inHangjun Zhan, Ph.D.(Chief Technology Officer and Co-Founder)

Co-investorsECEcoR1 CapitalFRFrazier Life SciencesILIllumina VenturesSASanofi VenturesVEvenBio PartnersVIVida Ventures+1 more

Co-investorsALAlta PartnersARARCH Venture PartnersDCDC Investment PartnersLOLongwood FundPAPathway to CuresATAtlas Venture+6 more

Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes.

BiotechHealthtechCambridge, US

Nick Lydon(Director)CSChristoph S. Lengauer(Executive Officer)inChristine Bellon(Executive Officer)inKyle Kuvalanka(Executive Officer)in

BoardAlexis Borisy(Executive Officer, Director)Daniel Lynch(Director)

Co-investorsF-F-Prime CapitalFOForesite CapitalRARA CapitalRIRidgeback CapitalRORoche Venture FundWEWellington Management+1 more

Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.

BiotechSan Mateo, US

GCGina Chapman(Executive Officer, Director)inAnup Radhakrishnan(Executive Officer)inCassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)

BoardAbraham Bassan(Director)

Co-investorsRERed Tree VentureSASamsara BioCapitalWEWellington ManagementALAlly Bridge GroupJAJanus Henderson InvestorsPEPerceptive Xontogeny Venture+1 more

Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies.

BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US

MPMatthew P. Jacobson(Co-founder)Scott R. Lokey(Director)DJDavid J. Earp(President & CEO)inPaul Park(Executive Officer)

BoardTSThilo Schroeder(Director)inWHWalter H. Moos(Director)

Co-investorsBEBerkeley CatalystHEHemisphere Ventures LLCJUJude GomilaLILifeforce CapitalMIMission Bay CapitalMIMission Biocapital+4 more

Delphia Therapeutics is a biotechnology company developing cancer medicines based on its activation lethality platform, aiming to create therapies effective on their own while combating resistance to targeted therapies.

BiotechHealthtechCambridge, US

KMKevin Marks(Founder)in

Co-investorsGVGV (Google Ventures)TATaiho Ventures, LLCALAlexandria

Diamond Therapeutics is a preclinical biotechnology company developing drug treatments for psychiatric and neurological disorders, with a focus on the pharmacology and therapeutic use of psychedelic compounds.

BiotechHealthtechMental HealthToronto, CA

JBJudy Blumstock(Chief Executive Officer, Founder, Director)inMichael B. McDonnell(Chief Medical Officer)inGrant McCutcheon(Chief Financial Officer)in

Co-investorsJLJLSNONoeticPAPalo Santo VCNENew Enterprise Associates (NEA)RARA Capital

EQRx was a Cambridge, MA biopharma that aimed to sell lower-priced novel drugs; it was acquired by Revolution Medicines in 2023.

Alexis Borisy(Founder)

Co-investorsANAndreessen HorowitzARArboretum VenturesARARCH Venture PartnersGVGV (Google Ventures)BABain CapitalCACasdin Capital+1 more

Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.

BiotechDeep TechMedical Devices

David Liu, PhD(Founder)ASAlan Saghatelian, PhD(Co-Founder)DLDavid LiuinASAlan Saghetelian

Co-investorsNENewpath PartnersCRCRV (Charles River Ventures)RARaptor GroupSASamsara BioCapitalBIBiotechnology Value FundCACasdin Capital+1 more

Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.

AI & Machine LearningFuture of WorkHR TechTokyo, JP

KKKazuki Kamiya(CEO)SISatoru Ichihara(COO)SHShinya Hayashi(CSO)HIHidefumi Iwaki(CFO)TSTomohiro Sasaki(Executive Officer (Product Development))

Co-investorsANANOBAKACACARTA VENTURES, Inc.SPSpiral VenturesAGAgent CapitalCACasdin CapitalINInvus+2 more

Flare is a Shopify app that calculates location-specific delivery dates, methods, cut-off times and rates at checkout based on a customer's exact postcode or ZIP code, down to individual zones.

E-commerceLogistics & Supply ChainRetail TechSaaSLondon, GB

DPDaniel Parekh-Hill(CEO)inAlex Hooper(CTO)in

Co-investorsENEntrepreneur FirstAGAgent CapitalBABase10 PartnersCACasdin CapitalINInovia CapitalINInvus+2 more

Flare Therapeutics develops small molecule medicines targeting transcription factors using a chemistry and proteomics platform that enables ligand discovery directly from cells.

AI & Machine LearningBiotechDeep TechHealthtech

JAJim Audia(Executive Vice President, Drug Discovery and Early Development, and Founding Scientist)JSJacob Stuckey(Senior Director, Biochemistry and Chemical Biology, and Founding Scientist)in

Co-investorsNENexTech VenturesPFPfizer VenturesTHThird Rock VenturesPFPfizer Venture InvestmentsSHShangBay Capital LLCAGAgent Capital

Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.

BiotechHealthtechMedical DevicesNew York, US

Co-investorsBRBrandon CapitalKLKleiner PerkinsNENew Enterprise Associates (NEA)PRProspect Venture PartnersRHRho Capital PartnersRHRho Ventures+3 more

Hexagon Bio develops novel payload mechanisms for antibody-drug conjugates (ADCs) aimed at overcoming resistance to current cancer treatments and expanding ADC indications.

BiotechDeep TechHealthtechMenlo Park, US

CJColin James Bell Harvey(Director)BTBrian T. Naughton(Director)inMHMaureen Hillenmeyer(CEO & Co-Founder)in

BoardAlex Kolich(Director)

Co-investorsATATEL VenturesB3B3 HoldingSOSoftBank Vision FundTHThe Column Group8V8VCCACasdin Capital+1 more

Iconovir is a biotechnology company focused on developing cancer treatments, with a stated mission to cure cancer and restore life to patients.

BiotechHealthtechNew York, US

SASean Algeo(Executive Officer, Promoter)inMAMark A. McCamish(Executive Officer, Director)inDMDavid M. Tanen(Executive Officer, Promoter)

BoardDCDavid Chang(Director, Promoter)HKHelen Kim(Director)JLJakob Loven(Director)in

Co-investorsGVGV (Google Ventures)WEWellington ManagementVIVida Ventures

IDRx discovers, develops and delivers medicines and vaccines focused on cancer, HIV, respiratory diseases, and infectious diseases.

BiotechMedical Devices

TCTim Clacksonin

Co-investorsANAndreessen HorowitzRARA Capital

ITM is a vertically integrated biotechnology company specializing in precision oncology through radioisotope production and radiopharmaceutical development, with clinical programs advanced through subsidiary Lumara Bio.

BiotechHealthtechMedical Devices

APAlexander Pironi(Executive Vice President, Global Head of Radioisotopes)inDr. Konstantin Zhernosekov(Chief Scientific Officer & Managing Director ITM Medical Isotopes & ITM Oncologics)

Co-investorsCACapmontRVRV Invest GmbH

Jounce Therapeutics was a Cambridge, MA clinical-stage biopharmaceutical company developing cancer immunotherapies, including antibodies targeting ICOS and LILRB2/ILT4, guided by a biomarker-driven discovery platform.

BiotechCambridge, US

KCKim C. Drapkin(Executive Officer)Anna L. Barry(Executive Officer)inRMRichard Murray(Executive Officer, Director)

BoardRTRobert Tepper(Director)inCPCary Pfeffer(Director)inRKRobert Kamen(Director)in

Co-investorsBOBoutique Venture PartnersGEGENERAL INCEPTIONSOSofinnova VenturesVEVenture Capital Investment ManagementTHThird Rock VenturesWEWellington Management

A biotechnology company developing cancer therapies for patients with unmet medical needs.

BiotechHealthtech

Co-investorsATAtlas VentureF-F-Prime CapitalEIEight Roads Ventures

Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases.

BiotechMedical DevicesSan Diego, US

Robert Hoffman(Founder; CEO & Head of Research)Craig Murphy, PhD(Founder; Chief Scientific Officer)Chris LeMasters, MBA(Founder; Executive Board Chairman)

Co-investorsFOForesite CapitalALAlexandriaLILilly Asia VenturesLOLongwood Fund

BiotechSan Diego, US

Stephen W. Kaldor(Executive Officer, Director, Promoter)Eric Murphy(Executive Officer, Director)

BoardBret Zbar(Director)Carl Gordon(Director)MRMichael Rome(Director)in

Co-investorsFOForesite CapitalVIViking GlobalJAJanus Henderson InvestorsRARA CapitalVEVenrock Healthcare Capital PartnersVIViking Global Investors

Kronos Bio was a clinical-stage biopharmaceutical company developing small molecule therapeutics that target deregulated transcription factor networks implicated in cancer.

BiotechNew York, US

Norbert Bischofberger, Ph.D.(Executive Officer, Director)Christopher Wilfong(Executive Officer)

BoardRebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)DMDavid M. Tanen(Executive Officer, Director, Promoter)Arie S. Belldegrun, M.D.(Director)

Co-investorsECEcoR1 CapitalGVGV (Google Ventures)VIVida VenturesBLBlackRockCOCommodore CapitalINInvus+2 more

Mariana Oncology, a Novartis company, develops precision radioligand therapies that deliver radioisotopes to diseased cells while limiting effects on healthy tissue.

BiotechHealthtechMedical Devices

Co-investorsACAccess BiotechnologyATAtlas VentureACAccess IndustriesFOForbionRARA Capital

Day One (part of Servier) is a biopharmaceutical company developing targeted oncology medicines, with a focus on cancers affecting patients of all ages, including pediatric low-grade glioma (pLGG).

BiotechHealthtechCambridge, US

MICHAEL J. KAUFMAN(Executive Officer)inDonald Bergstrom(Executive Officer)inAPANNA PROTOPAPAS(Executive Officer, Director)TLTimothy Lowinger(Executive Officer)Eva Jack(Executive Officer)Wayne Foster(Executive Officer)

Co-investorsBABain Capital Life SciencesF-F-Prime CapitalLILightstone VenturesNENew Enterprise Associates (NEA)PFPfizer Venture InvestmentsRHRho Ventures+3 more

Mirati develops investigational medicines and treatments for patients with multiple myeloma and other oncology indications.

BiotechHealthtechMedical Devices

Co-investorsAVAvoro Capital AdvisorsBIBioBritBOBoxer Capital, LLCPAPappas Capital

A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.

Biotech

Timur Yusufzai(Founder)inAPAsit Parikh(Chief Executive Officer)in

Co-investorsLILifeSci Venture PartnersTHThird Rock VenturesALAlexandriaCACasdin CapitalCRCreacion VenturesGOGoldman Sachs+4 more

BiotechCambridge, US

RGRichard Gaynor, M.D.(Executive Officer)inRobert Ang, M.D.(Executive Officer)YAYasir Al-Wakeel(Executive Officer)inEric Lander(Director)Hugh Dowd(Executive Officer, Director)

BoardCary Pfeffer, M.D.(Director)

Co-investorsSOSofinnova VenturesCLClal Biotechnology IndustriesTHThird Rock VenturesWEWellington Management

Nextop operates a mobile content delivery network that improves connectivity between mobile applications and their back ends.

Cloud ComputingData & InfrastructureDeveloper ToolsEnterprise Software

BCBrien Colwell(CEO)in

Co-investorsY Y CombinatorANAndreessen HorowitzLILightspeed Venture PartnersRARA Capital

Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.

BiotechDigital HealthMedical Devices

Co-investorsCUCurative VenturesFOForesite CapitalRIRidgeback CapitalTHThe Column GroupVIVida Ventures

The Faculty of Pharmacy and Biochemistry offers pharmacy and biochemistry degree programs, including a Pharmacy programme in English aligned with EU Directive 2005/36/EC for EU/EEA registration.

EdTech

Co-investorsVEVesna AdvisorsRARA CapitalTHThe Column Group

PMV Pharma is a precision oncology company developing therapies that selectively target mutant p53 to treat cancers whose tumors carry p53 gene mutations.

BiotechHealthtechLongevityCranbury, US

DHDavid H. Mack, Ph.D.(Founder)inDavid Mack(Executive Officer, Director)Arnold Levine(Co-Founder & Member, Scientific Advisory Board)David H. Mack(Co-Founder, President & CEO)Thomas Shenk(Co-Founder)Deepika Jalota(Chief Development Officer)

Co-investorsAVAvoro Capital AdvisorsOUOUP (Osage University Partners)RARA CapitalVIViking GlobalWEWellington ManagementOROrbiMed

Acquired by Genmab in April 2024.

Co-investorsB B Capital GroupB4B4 CapitalHOHongShan Capital GroupLALAVLILifeSci Venture PartnersLILilly Asia Ventures+2 more

Sail Biomedicines develops RNA-based medicines using a platform integrating Endless RNA and targeted nanoparticle delivery technology.

AI & Machine LearningBiotechDeep TechCambridge, US

John Mendlein(Executive Chairman)

Co-investorsFLFlagship PioneeringQUQuan CapitalSTStage 1 Ventures

BiotechBoston, US

AFAdam Friedman(Executive Officer, Director)inGGGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)inDSDarrin Stuart(Executive Officer)inErica Jackson(Executive Officer)inAmanda Valentino(Executive Officer)

Co-investorsATAtlas VentureAVAvoro Capital AdvisorsECEcoR1 CapitalFRFrazier Life SciencesVIVida VenturesABAbingworth+3 more

BiotechDigital HealthMedical DevicesSeattle, US

PAPeter A. Thompson(Executive Officer, Director)in

Co-investorsECEcoR1 CapitalPOPontifax Venture CapitalRARA CapitalUSUS Venture PartnersALAlexandriaOROrbiMed

Stipple Bio develops targeted oncology therapies that act on tumor-specific cell surface epitopes to expand druggable targets and improve therapeutic index for cancer patients.

BiotechHealthtechCambridge, US

ARAaron Ring(Co-founder)inAMAashish Manglik(Co-founder)inJeff Landau(Chief Executive Officer)inRGRoland Gendron(Chief Business Officer)inMZMichelle Zhang(Chief Scientific Officer)in

BoardVAVineeta Agarwala(Director)in

Co-investorsRARA CapitalANAndreessen HorowitzGVGV (Google Ventures)MAMagnetic VenturesOMOMX VenturesAXAxial VC+1 more

A drug discovery company founded by an experienced medicinal chemistry team with expertise in successful pharmaceutical development and clinical advancement.

BiotechDeep TechMedical DevicesWilmington, US

Liangxing Wu(Executive Officer, Director)inWenqing Yao(Executive Officer, Director)inTing Feng(Director)Wenqing Yao, Ph.D.(Founder & CEO)Liangxing Wu, Ph.D.(Co-Founder & SVP Drug Discovery)

BoardRHReid Huber(Director)in

Co-investorsTHThe Innovation SpaceTHThird Rock Ventures

BiotechCambridge, US

William C. Shakespeare(Director)in

BoardIDIain Dukes(Executive Officer, Director)inMRMichael Rome(Director)inCGCarl Gordon(Director)in

Co-investorsFOForesite CapitalLOLongitude CapitalNENexTech VenturesOMOmega FundsOROrbiMedPOPontifax Venture Capital+2 more

Tubulis develops antibody-drug conjugates (ADCs) for cancer treatment, using proprietary conjugation platform technologies to create tumor-targeting therapeutics.

BiotechDeep TechMedical DevicesPlanegg-Martinsried, DE

DSDominik Schumacher(Co-founder & CEO)inJonas Helma-Smets(Co-founder & Chief Scientific Officer)Christian Hackenberger(Scientific Co-founder)

Co-investorsANAndera PartnersBIBioMedPartnersEQEQT Life SciencesNENexTech VenturesASAscenta CapitalBABayern Kapital+7 more

Zenith-TX is a drug discovery company focused on targeting high-value proteins that have historically been considered undruggable, using biological quality control mechanisms.

BiotechDeep Tech

AIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA.

AI & Machine LearningBiotechDeep TechHealthtechStanford, US

TSThorsten Stafforst(Chairman of the Board of Directors)inKEKris ElveruminTBTodd Bazemore(Chief Executive Officer)inJin (Billy) Li(Treasurer and Secretary)inPaul Vogel(Chief Executive Officer and President)in

BoardRodger Novak(Chair)in

Co-investors+N+ND CapitalARARCH Venture PartnersFOForbionVEVenrockFAFast Track InitiativeLILifelink+3 more